<DOC>
	<DOCNO>NCT00516438</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose drug KU-0059436 give combination topotecan chemotherapy patient advance solid tumour</brief_summary>
	<brief_title>Study Assess Safety Tolerability PARP Inhibitor Combination With Topotecan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histological cytological diagnosis advance solid tumour suitable effective therapy exist ; Evaluable disease Adequate bone marrow , hepatic renal function Any chemotherapy , radiotherapy ( except palliative ) , endocrine immunotherapy within 4 week prior entry ; major surgery 4 week enter study Heavily pre treat patient &gt; 2 previous chemotherapy regimens metastatic disease Coexisting active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>malignant solid tumour</keyword>
	<keyword>Poly ( ADP ribose )</keyword>
	<keyword>polymerase</keyword>
</DOC>